Short-term Administration of Glucagon-like Peptide-2. Effects on Bone Mineral Density and Markers of Bone Turnover in Short-Bowel Patients with No Colon

Haderslev, Kent V.; Jeppesen, Palle Bekker; Hartmann, Bolette; Thulesen, Jesper; Sørensen, Helle; Graff, Jesper; Hansen, Birthe; Tofteng, Flemming; Poulsen, Steen Seier; Madsen, Jakob Torp; Holst, Jens J.; Staun, Michael; Mortensen, Per Brøbech

doi:10.1080/003655202317316006

Cited by 91 publications

(57 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therapies to minimize BMD loss for patients on TPN include bisphosphonates, calcitonin, and calcium supplementation; however, experimental approaches using subcutaneous PTH may be beneficial because of the osteoblastic effect of this agent. Another promising agent, glucagon-like-peptide-2, increased BMD in a pilot study of patients with short bowel syndrome [47].…”

Section: Bone Diseasementioning

confidence: 99%

Metabolic and catheter complications of parenteral nutrition

Ghabril

Aranda-Michel

Scolapio

2004

Curr Gastroenterol Rep

View full text Add to dashboard Cite

Since its introduction in the 1960s, total parenteral nutrition (TPN) has played a vital role in improving clinical outcomes for patients with acute and chronic illnesses. The evolution of TPN solutions and vascular access techniques, combined with an increased awareness and better understanding of the physiology of TPN, have improved the safety of this therapy. Nevertheless, complications are not uncommon and can be life threatening. This article provides an updated review on the metabolic and catheter complications associated with TPN.

show abstract

Section: Bone Diseasementioning

confidence: 99%

Metabolic and catheter complications of parenteral nutrition

Ghabril

Aranda-Michel

Scolapio

2004

Curr Gastroenterol Rep

View full text Add to dashboard Cite

show abstract

“…Glucagon-like peptide-2 (GLP-2), an enteroendocrine L-cell derived hormone, is an inhibitor of gastric emptying. GLP-2 also decreases bone resorption (26) and has positive effect on bone mineralization (27). Overall, the nutritional, metabolic and hormonal changes produced by rapid weight loss favor bone resorption.…”

Section: Osteometabolic Changes After Roux-en-y Gastric Bypassmentioning

confidence: 99%

Obesity, diabetes mellitus and last but not least, osteoporosis

Paula

Rosen

2010

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

SummaryKnowledge about the influence of bone on intermediary metabolism corresponds to a developing area that has gained prominence. The old concept of bone and adipose tissues as inert metabolic tissues, with minor contributions to metabolic adaptations has been reconsidered in light of findings that bone is involved in the development of insulin sensitivity. Similarly adipose tissue exerts important influences on bone mass development and maintenance. Moreover, the use of drugs in the treatment of metabolic disorders such as diabetes mellitus can impact bone metabolism. These networks linking osteoporosis to obesity and diabetes mellitus have reinvigorated investigations in the pathophysiology of osteoporosis. The present review examines this aspect and calls attention to health care providers and potential treatments of skeletal disorder. Arq Bras Endocrinol Metab. 2010;54(2):150-7 Keywords Osteoporosis; obesity; diabetes mellitus; bariatric surgery; thiazolidinediones SumárioO estudo sobre a influência do tecido ósseo no metabolismo intermediário corresponde a uma área em desenvolvimento que tem ganho recente destaque. O conceito prévio de que os tecidos ósseo e adiposo seriam metabolicamente inativos foi reconsiderado à luz de estudos que mostram que metabólitos ósseos podem influenciar a sensibilidade à insulina. Da mesma forma, o tecido adiposo exerce influência importante no desenvolvimento e na manutenção da massa óssea. Além disso, o uso de drogas no tratamento de doenças metabólicas como o diabetes melito pode afetar o metabolismo ósseo. A rede de conexões existentes que ligam a osteoporose à obesidade e ao diabetes melito tem revigorado investigações sobre a fisiopatologia da osteoporose. A presente revisão analisa esse aspecto e destaca a necessidade de atenção para esses pontos por parte de serviços de saúde voltados para o atendimento de diabetes melito e da obesidade quanto ao potencial impacto sobre o tecido ósseo. Arq Bras Endocrinol Metab.

show abstract

“…Vitamin D concentrations are uniformly low in SBS patients, though its link to MBD in SBS patients is not as robust as found with celiac disease or primary biliary cirrhosis [86]. Interestingly, GH [87] and GLP-2 [88] may increase bone density in SBS patients. A parenteral formulation for vitamin D supplementation would be of significant benefit to the SBS patient in the treatment of their osteoporosis, but is not currently commercially available.…”

Section: Osteoporosismentioning

confidence: 89%

Management and Complications of Short Bowel Syndrome: an Updated Review

Carroll

Benedetti

Schowalter

et al. 2016

Curr Gastroenterol Rep

View full text Add to dashboard Cite

Short bowel syndrome (SBS) is defined as loss of bowel mass from surgical resection, congenital defects, or disease. Intestinal failure (IF) includes the subset of SBS unable to meet nutrition needs with enteral supplements and requires parenteral nutrition (PN). The parenteral treatment of SBS is now a half-century old. Recent pharmacologic treatment (GLP-2 analogues) has begun to make a significant impact in the care and ultimate management of these patients such that the possibility of reducing PN requirements in formerly PN-dependent patients is a now a real possibility. Finally, newer understanding and possible treatment for some of the complications related to IF have more recently evolved and will be an emphasis of this report. This review will focus on developments over the last 10 years with the goal of updating the reader to new advances in our understanding of the care and feeding of the SBS patient.

show abstract

Short-term Administration of Glucagon-like Peptide-2. Effects on Bone Mineral Density and Markers of Bone Turnover in Short-Bowel Patients with No Colon

Abstract: A 5-week GLP-2 administration significantly increased spinal BMD in short-bowel patients with no colon. The mechanism by which GLP-2 affects bone metabolism remains unclear, but may be related to an increased mineralization of bone resulting from an improved intestinal calcium absorption.

Cited by 91 publications

References 31 publications

Metabolic and catheter complications of parenteral nutrition

Metabolic and catheter complications of parenteral nutrition

Obesity, diabetes mellitus and last but not least, osteoporosis

Management and Complications of Short Bowel Syndrome: an Updated Review

Contact Info

Product

Resources

About